A new study has revealed that even a short term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) among patients receiving antithrombotic therapy (to prevent the formation of blood clots) after a myocardial infarction (MI; heart attack), was associated with an increased risk of bleeding and events such as heart attack, stroke or cardiovascular death.
Guidelines recommend that all patients with MI should be prescribed dual antithrombotic therapy, aspirin and clopidogrel, for up to a year and one agent thereafter. Although bleeding risks associated with antithrombotic agents are increased by NSAIDs, certain NSAID agents such as ibuprofen may also impede the antithrombotic effects of aspirin and may increase risk of cardiovascular events. These risks are of considerable public health concern, given the widespread use of NSAIDs.
Researchers examined the risk of bleeding and cardiovascular events among patients with prior MI taking antithrombotic drugs and for whom NSAID therapy was then prescribed. The study included 61,971 patients with an average age of 68 years, and of these, 34 percent filled at least 1 NSAID prescription. The number of deaths during a median follow-up of 3.5 years was 18,105 or 29.2 percent. Researchers reported a total of 5,288 bleeding events (8.5 percent) and 18,568 cardiovascular events (30.0 percent). The analysis indicated that there was about twice the risk of bleeding with NSAID treatment compared with no NSAID treatment, and the cardiovascular risk was also increased. The increased risk of bleeding and cardiovascular events was evident with accompanying use of NSAIDs, regardless of antithrombotic treatment, NSAID type, or duration of use.
The study is published in the 'JAMA'.